The Francis Crick Institute, the UK’s newest biomedical research facility, and GSK, the UK’s largest healthcare company, are to partner on an open innovation collaboration exploring new avenues of medical research and drug discovery across a broad range of diseases, with a view to achieving breakthroughs in the understanding of human disease and accelerate the discovery of new medicines.
This is the first collaboration to be established between the Crick and a pharmaceutical company. The GSK – Crick open science collaboration will combine the specialised discovery science knowledge of the Crick’s scientists with the pharmaceutical R&D expertise of GSK scientists, opening up possibilities for scientific discovery that would not be possible for each partner working alone.
Teams of scientists from each organisation will work side-by-side in integrated teams at the Crick’s world-leading centre of biomedical research in the heart of London and GSK’s global R&D hub in Stevenage. The close proximity of these two sites and the institutions’ complementary areas of expertise will create a fertile ground for collaborative, innovative research – exposing scientists to new ways of thinking and building capability within each organisation.
Increased interactions between Crick and GSK scientists will benefit both sides, introducing new ways of working and stimulating the development of novel approaches to problems. GSK and the Crick believe that this fluid interchange of skills and ideas could lead to significant discoveries in the basic scientific understanding of human disease, ultimately improving the success rate for discovering new medicines.